Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Want to see AU:AVE full AI Analyst Report?
Top Page
Avecho Biotechnology Limited
(Sydney:AVE)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.01
▲(20.00% Upside)
Action:ReiteratedDate:04/30/26
The score is held back primarily by persistent net losses and a shrinking equity base despite improved revenue growth. Positive 2025 operating/free cash flow and low leverage provide some support, while technicals are mixed due to extreme RSI and valuation is pressured by negative earnings and no dividend yield data.
Positive Factors
Proprietary TPM platform
Avecho’s TPM is a durable technical asset that supports formulation and absorption advantages across pharmaceuticals and nutraceuticals. As a platform it enables licensing, partner co-development, and recurring royalties, creating scalable, asset-light growth pathways over months to years.
Negative Factors
Persistent operating and net losses
Sustained, sizable operating and net losses indicate the business has not yet achieved profitable scale. Continued deficits can force dilutive capital raises, constrain R&D prioritisation, and erode investor confidence, posing a structural risk to capital continuity if profitability isn’t reached.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary TPM platform
Avecho’s TPM is a durable technical asset that supports formulation and absorption advantages across pharmaceuticals and nutraceuticals. As a platform it enables licensing, partner co-development, and recurring royalties, creating scalable, asset-light growth pathways over months to years.
Read all positive factors
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$44.08M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth9.28%
EPS Growth-40.00%
CountryAU
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding3,673,463,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutr...
How the Company Makes Money
Avecho’s monetisation model is primarily based on commercialising its proprietary TPM drug-delivery technology and any products formulated using it. Revenue can be generated through (1) licensing TPM to partners for use in their products, which ty...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | |||||
| Total Assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | |||||
| Free Cash Flow | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | 0.00 | -15.73K | 0.00 | -53.12K | -202.82K |
| Financing Cash Flow | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$44.08M | -6.66 | -370.40% | ― | 9.28% | -40.00% | |
46 Neutral | AU$23.04M | -3.69 | 2509.60% | ― | ― | -137.97% | |
45 Neutral | AU$7.29M | -0.15 | 2844.96% | ― | ― | 62.07% | |
45 Neutral | AU$14.24M | -1.59 | -91.88% | ― | -55.21% | 36.36% | |
43 Neutral | AU$9.80M | -1.29 | -43.95% | ― | 14.30% | 41.93% | |
42 Neutral | AU$28.32M | -6.84 | -49.25% | ― | ― | 25.00% |
* Healthcare Sector Average
AU:AVE
Avecho Biotechnology Limited
0.01
<0.01
20.00%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:IMC
Immuron Limited
0.03
-0.04
-54.55%
AU:NOX
Noxopharm Ltd.
0.08
>-0.01
-6.25%
AU:CHM
Chimeric Therapeutics Ltd.
0.17
>-0.01
-2.94%
AU:MEM
Memphasys Ltd
―
―
―
Avecho Biotechnology Limited Corporate Events
Avecho Flags Imminent Option Expiry as It Advances CBD Insomnia Trial
Apr 29, 2026
Avecho Biotechnology has notified holders of its listed options (ASX: AVEOA) that the options, exercisable at $0.012, will expire at 5:00pm AEST on 10 May 2026, with trading to cease on 4 May 2026. Option holders may choose to exercise all or part...
Avecho Exceeds Phase III Insomnia Trial Target as Key Interim Read-Out Nears
Apr 28, 2026
Avecho Biotechnology has surpassed its recruitment target for the interim analysis of its pivotal Phase III trial of a TPM-enhanced CBD soft-gel capsule for insomnia, randomising 244 patients, 16% above plan, to strengthen statistical power. The m...
Avecho sets 2026 AGM date and shifts to digital meeting materials
Apr 23, 2026
Avecho Biotechnology Limited has scheduled its Annual General Meeting for Tuesday, 26 May 2026 at 1:00pm AEST, to be held at Grant Thornton’s offices in Collins Square, Melbourne. Shareholders are encouraged to participate either in person o...
Avecho to Showcase CBD Insomnia Program at NWR Healthcare Conference
Mar 23, 2026
Avecho Biotechnology will present at the NWR Virtual Healthcare Conference on 25 March 2026, with CEO Dr Paul Gavin outlining the company’s progress and making the session accessible to investors via live stream and subsequent online replay....
Avecho hits key Phase III recruitment milestone in CBD insomnia trial
Mar 1, 2026
Avecho Biotechnology has completed recruitment of roughly 210 patients for the interim analysis cohort of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, with results expected in June 2026. The study is intended to ...
Avecho Files Updated Corporate Governance Statement and Appendix 4G with ASX
Feb 27, 2026
Avecho Biotechnology Limited has lodged its Corporate Governance Statement for the financial year ended 31 December 2025, confirming that the document is current as of 27 February 2026 and has been approved by the board. The statement, accessible ...
Avecho Widens Annual Loss Despite Higher Revenue as Development Spending Continues
Feb 27, 2026
Avecho Biotechnology Limited has reported a 9.3% increase in revenues from ordinary activities to $1.24 million for the year ended 31 December 2025, while its net tangible assets per ordinary security declined to 0.04 cents from 0.10 cents. The co...
Avecho nears key Phase III milestone as CEO showcases CBD insomnia program at healthcare forum
Feb 4, 2026
Avecho Biotechnology has announced that CEO Dr Paul Gavin will present at the Euroz Hartleys Healthcare Forum, where he will provide an update on the company’s pivotal Phase III clinical trial of its CBD TPM soft-gel capsule for insomnia and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.